Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 115,672 shares, an increase of 32.9% from the December 15th total of 87,064 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average trading volume of 217,009 shares, the short-interest ratio is currently 0.5 days. Based on an average trading volume of 217,009 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the company’s stock are short sold.

Inventiva Price Performance

Shares of Inventiva stock traded up $0.39 during mid-day trading on Monday, hitting $6.51. 387,465 shares of the stock were exchanged, compared to its average volume of 393,046. Inventiva has a 12 month low of $2.11 and a 12 month high of $7.98. The company has a 50-day simple moving average of $4.51 and a 200 day simple moving average of $4.58.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC purchased a new stake in shares of Inventiva during the 3rd quarter valued at $649,000. Wealth Enhancement Advisory Services LLC increased its holdings in Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after buying an additional 9,212 shares during the last quarter. NewEdge Advisors LLC bought a new stake in Inventiva in the third quarter worth about $116,000. Finally, Creative Planning purchased a new position in Inventiva in the second quarter valued at about $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Analysts Set New Price Targets

IVA has been the subject of several recent research reports. HC Wainwright boosted their price objective on Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Wall Street Zen raised shares of Inventiva to a “hold” rating in a research report on Saturday, October 18th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price objective on shares of Inventiva in a report on Tuesday, September 30th. Leerink Partners began coverage on shares of Inventiva in a research note on Monday, January 12th. They issued an “outperform” rating and a $12.00 price objective on the stock. Finally, Guggenheim reduced their price objective on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $16.00.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.